PE20050126A1 - Compuestos del 2-fenil-3-dimetilamino-propano en la terapia de sintomaticas depresivas - Google Patents

Compuestos del 2-fenil-3-dimetilamino-propano en la terapia de sintomaticas depresivas

Info

Publication number
PE20050126A1
PE20050126A1 PE2003000715A PE2003000715A PE20050126A1 PE 20050126 A1 PE20050126 A1 PE 20050126A1 PE 2003000715 A PE2003000715 A PE 2003000715A PE 2003000715 A PE2003000715 A PE 2003000715A PE 20050126 A1 PE20050126 A1 PE 20050126A1
Authority
PE
Peru
Prior art keywords
phenyl
dimethylamine
therapy
dimethylaminomethyl
cyclohexyl
Prior art date
Application number
PE2003000715A
Other languages
English (en)
Inventor
Elmar Friderichs
Ulrich Jahnel
Oswald Zimmer
Werner Englberger
Helmut Buschmann
Jorg Holenz
Hagen-Heinrich Hennies
Derek Saunders
Wolfgang Strassburger
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20050126A1 publication Critical patent/PE20050126A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C07C291/04Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds containing amino-oxide bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C305/00Esters of sulfuric acids
    • C07C305/22Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings
    • C07C305/24Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings of non-condensed six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA LOS COMPUESTOS 3-(2-DIMETILAMINOMETIL-CICLOHEXIL)-FENOL, 4-(2-DIMETILAMINOMETIL-CICLOHEXIL)-CATECOL, 4-(2-DIMETILAMINOMETIL-CICLOHEXIL)-BENCEN-1,2-DIOL, N-OXIDO DE (1R,2R)-[2-(3-METOXI-FENIL)-CICLOHEXILMETIL]-DIMETIL-AMINA, ENTRE OTROS, COMO SUS RACEMATOS, ESTEREOISOMEROS PUROS EN FORMA AISLADA O DE ACIDOS O BASES. TAMBIEN REFERIDA A LA PREPARACION DE DICHOS ESTEREOISOMEROS, LOS QUE SE ENCUENTRAN DE PREFERENCIA COMO 1R,2R Y SON UTILES EN EL TRATAMIENTO DE DOLORES AGUDOS, VISCERALES, CRONICOS, NEUROPATICOS O DE CANCER, INCONTINENCIA URINARIA
PE2003000715A 2002-07-19 2003-07-17 Compuestos del 2-fenil-3-dimetilamino-propano en la terapia de sintomaticas depresivas PE20050126A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10233048A DE10233048A1 (de) 2002-07-19 2002-07-19 Verwendung von 1-Phenyl-3dimethylamino-propanverbindungen zur Therapie von depressiven Symptomatiken

Publications (1)

Publication Number Publication Date
PE20050126A1 true PE20050126A1 (es) 2005-04-19

Family

ID=29796483

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000715A PE20050126A1 (es) 2002-07-19 2003-07-17 Compuestos del 2-fenil-3-dimetilamino-propano en la terapia de sintomaticas depresivas

Country Status (26)

Country Link
EP (1) EP1530462B1 (es)
JP (1) JP4616644B2 (es)
KR (1) KR101056343B1 (es)
CN (1) CN1697651B (es)
AR (1) AR040574A1 (es)
AT (1) ATE491442T1 (es)
AU (1) AU2003263179B2 (es)
BR (1) BR0312854A (es)
CA (1) CA2492876C (es)
CO (1) CO5680411A2 (es)
CY (1) CY1111607T1 (es)
DE (2) DE10233048A1 (es)
DK (1) DK1530462T3 (es)
EC (1) ECSP055583A (es)
ES (1) ES2357947T3 (es)
HK (1) HK1075843A1 (es)
IL (2) IL166363A (es)
MX (1) MXPA05000791A (es)
NO (1) NO333812B1 (es)
PE (1) PE20050126A1 (es)
PL (1) PL214703B1 (es)
PT (1) PT1530462E (es)
RU (1) RU2387446C2 (es)
SI (1) SI1530462T1 (es)
WO (1) WO2004009067A1 (es)
ZA (1) ZA200501428B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3241550T3 (da) * 2002-11-22 2020-08-24 Gruenenthal Gmbh Anvendelse af (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol til behandling af inflammatoriske smerter
DE10356362A1 (de) 2003-11-28 2005-06-23 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie von Angststörungen
WO2006038084A1 (en) * 2004-10-01 2006-04-13 Neurocure Ltd Use of pharmaceutical compositions of lofepramine for the treatment of adhd, cfs, fm and depression
EP2336103A3 (de) * 2005-07-22 2011-07-20 Grünenthal GmbH HCL-Polymorphe von 3-[2-(Dimethylamino)methyl-(cyclohex-1-yl)]phenol
DE102005034973A1 (de) * 2005-07-22 2007-02-15 Grünenthal GmbH Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen
EP3296289A3 (en) 2007-05-31 2018-06-20 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
EP2085081A1 (de) * 2008-02-04 2009-08-05 Grünenthal GmbH 3-(2-Dimethylaminomethyl-cyclohexyl)-phenol gegen polyneuropathischen Schmerz
US20110295038A1 (en) * 2010-05-28 2011-12-01 Gruenenthal Gmbh Process for the Preparation of Substituted 1-aminomethyl-2-phenyl-cyclohexane Compounds
WO2012100423A1 (en) * 2011-01-27 2012-08-02 Eli Lilly And Company Analgesic compounds, methods, and formulations
US8853393B2 (en) 2011-07-29 2014-10-07 Anhui New Star Pharmaceutical Development Co., Ltd. Intermediate for preparing tapentadol or analogues thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525137C2 (de) * 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe
PE20010623A1 (es) * 1999-10-05 2001-07-07 Gruenenthal Chemie Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria
JP2001233762A (ja) * 2000-02-21 2001-08-28 Gruenenthal Gmbh O−デスメチル−n−モノ−デスメチル−トラマドールの使用方法
DE10059411A1 (de) * 2000-11-30 2002-06-13 Gruenenthal Gmbh Verwendung von 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur Therapie der Harninkontinenz

Also Published As

Publication number Publication date
DE50313329D1 (de) 2011-01-27
CN1697651B (zh) 2011-09-21
ES2357947T3 (es) 2011-05-04
ZA200501428B (en) 2006-09-27
EP1530462A1 (de) 2005-05-18
RU2005104821A (ru) 2006-01-20
SI1530462T1 (sl) 2011-03-31
CA2492876C (en) 2011-06-14
DE10233048A1 (de) 2004-01-29
CA2492876A1 (en) 2004-01-29
WO2004009067A1 (de) 2004-01-29
PL375629A1 (en) 2005-12-12
EP1530462B1 (de) 2010-12-15
KR20050019909A (ko) 2005-03-03
PT1530462E (pt) 2011-02-22
CO5680411A2 (es) 2006-09-29
MXPA05000791A (es) 2005-10-19
RU2387446C2 (ru) 2010-04-27
ATE491442T1 (de) 2011-01-15
JP2006511453A (ja) 2006-04-06
AU2003263179B2 (en) 2009-10-22
JP4616644B2 (ja) 2011-01-19
DK1530462T3 (da) 2011-02-14
IL166363A0 (en) 2006-01-16
KR101056343B1 (ko) 2011-08-12
AU2003263179A1 (en) 2004-02-09
HK1075843A1 (en) 2005-12-30
CN1697651A (zh) 2005-11-16
NO20050861L (no) 2005-02-17
IL209789A0 (en) 2011-02-28
ECSP055583A (es) 2005-04-18
BR0312854A (pt) 2005-04-19
PL214703B1 (pl) 2013-09-30
AR040574A1 (es) 2005-04-13
NO333812B1 (no) 2013-09-23
CY1111607T1 (el) 2015-10-07
IL166363A (en) 2012-05-31

Similar Documents

Publication Publication Date Title
ECSP077360A (es) Compuestos sulfonamida
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
GT200600092A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
PA8537401A1 (es) Diaminotiazoles
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
PA8779701A1 (es) Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
ES2572454T3 (es) Tratamiento de enfermedades mediadas por los linfocitos T
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
CY1110889T1 (el) C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους
CL2007002450A1 (es) Forma polimorfica i del enantiomero levogiro o dextrogiro de modafinilo; su procedimiento de preparacion; y composicion farmaceutica que los comprende (divisional solicitud 2693-03).
CR20110477A (es) Inhibidores de enzimas de proteina cinasa activadas por mitogeno p38
ECSP066355A (es) Compuestos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de la colecistocinina 2
NI200600094A (es) Compuesto heterociclicos fusionados
PE20050126A1 (es) Compuestos del 2-fenil-3-dimetilamino-propano en la terapia de sintomaticas depresivas
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
AR059390A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
ATE507878T1 (de) Gerät für intensitätsmodulierte kleinraumbestrahlungstherapie
EA200801560A1 (ru) Бифенилкарбоксамиды
CL2008003022A1 (es) Composicion farmaceutica que comprende n-(3-metoxi-5-metilpirazin-2-il)-2-(4-{1,3,4-oxadiazol-2-il}fenil)piridin-3-sulfonamida con manitol y celulosa microcristalina; y uso para el tratamiento del cancer de prostata, de ovario y de vejiga, entre otros.
SV2009003403A (es) Extrudidos con enmascaramiento del sabor mejorado
EA201170672A1 (ru) Соединения, пригодные для лечения целлюлита
AR053385A1 (es) Genes y proteinas novedosos de brachyspira hyodysenteriae y uso de los mismos para diagnostico y terapia
WO2004110245A3 (en) Combination therapy for cancer treatment
ES2491565T3 (es) Agente de transfección

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed